Unknown

Dataset Information

0

Research Progress on PARP14 as a Drug Target.


ABSTRACT: Poly-adenosine diphosphate-ribose polymerase (PARP) implements posttranslational mono- or poly-ADP-ribosylation modification of target proteins. Among the known 18 members in the enormous family of PARP enzymes, several investigations about PARP1, PARP2, and PARP5a/5b have been launched in the past few decades; more specifically, PARP14 is gradually emerging as a promising drug target. An intact PARP14 (also named ARTD8 or BAL2) is constructed by macro1, macro2, macro3, WWE, and the catalytic domain. PARP14 takes advantage of nicotinamide adenine dinucleotide (NAD+) as a metabolic substrate to conduct mono-ADP-ribosylation modification on target proteins, taking part in cellular responses and signaling pathways in the immune system. Therefore, PARP14 has been considered a fascinating target for treatment of tumors and allergic inflammation. More importantly, PARP14 could be a potential target for a chemosensitizer based on the theory of synthetic lethality and its unique role in homologous recombination DNA repair. This review first gives a brief introduction on several representative PARP members. Subsequently, current literatures are presented to reveal the molecular mechanisms of PARP14 as a novel drug target for cancers (e.g., diffuse large B-cell lymphoma, multiple myeloma, prostate cancer, and hepatocellular carcinoma) and allergic inflammatory. Finally, potential PARP inhibitor-associated adverse effects are discussed. The review could be a meaningful reference for innovative drug or chemosensitizer discovery targeting to PARP14.

SUBMITTER: Qin W 

PROVIDER: S-EPMC6411704 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

Research Progress on PARP14 as a Drug Target.

Qin Wei W   Wu Hong-Jie HJ   Cao Lu-Qi LQ   Li Hui-Jin HJ   He Chun-Xia CX   Zhao Dong D   Xing Lu L   Li Peng-Quan PQ   Jin Xi X   Cao Hui-Ling HL  

Frontiers in pharmacology 20190305


Poly-adenosine diphosphate-ribose polymerase (PARP) implements posttranslational mono- or poly-ADP-ribosylation modification of target proteins. Among the known 18 members in the enormous family of PARP enzymes, several investigations about PARP1, PARP2, and PARP5a/5b have been launched in the past few decades; more specifically, PARP14 is gradually emerging as a promising drug target. An intact PARP14 (also named ARTD8 or BAL2) is constructed by macro1, macro2, macro3, WWE, and the catalytic do  ...[more]

Similar Datasets

| S-EPMC7220569 | biostudies-literature
| S-EPMC5295238 | biostudies-literature
| S-EPMC8450320 | biostudies-literature
| S-EPMC9417990 | biostudies-literature
| S-EPMC11374297 | biostudies-literature
| S-EPMC9177940 | biostudies-literature
| S-EPMC8263870 | biostudies-literature
| S-EPMC9860488 | biostudies-literature
| S-EPMC8976206 | biostudies-literature
| S-EPMC10655051 | biostudies-literature